FDA nominee puts speed and China competition at center of hearing

Heidi Overton, President Trump’s choice to lead the Food and Drug Administration, is preparing to make speed a central theme of her appearance before a Senate committee on Thursday, according to an advance copy of her opening statement obtained by STAT.

Overton is expected to argue that the FDA must work more efficiently if the United States is to keep pace with China’s rapidly expanding biotechnology sector. Her statement presents lengthy or restrictive regulatory requirements as a risk to American investment, saying they can encourage companies and funding to move overseas.

The nominee’s message would place drug development at the heart of a broader competition between the two countries. In the statement, she says China has found methods for moving new therapies forward more quickly and at lower cost. Her proposed response is to accelerate the FDA’s work while maintaining the agency’s role in overseeing clinical trials and medicines.

A mandate to move faster

Overton says Trump has given her a direct instruction if the Senate confirms her: “go fast.” The phrase captures the approach she plans to present to lawmakers, with an emphasis on reducing delays across the process that takes potential treatments from research to patients.

Her statement does not describe a specific timetable or list particular FDA rules she would change. Instead, it sets out a broad goal of making the agency more efficient and ensuring that its work supports faster development of therapies. Overton links that goal to the need to compete for biotechnology investment, particularly as China’s industry advances.

The FDA’s work affects the path followed by new drugs and other therapies before they can reach patients. Clinical trials are a significant part of that path. Overton says she would continue the administration’s efforts to accelerate trials through Operation Trialblazer, an initiative that began earlier this year.

She also says the effort would extend beyond a single program. If confirmed, she plans to work with the FDA’s career staff to examine the various parts of clinical research and drug development. Her stated aim is to optimize those processes and make faster access to cures a shared priority throughout the agency.

The FDA’s role in the competition

The statement frames regulation and innovation as closely connected. Overton’s argument is that requirements intended to protect the integrity of medical research can also become obstacles if they are slow or unnecessarily difficult to navigate. In her view, the resulting delays may affect where companies choose to invest and develop products.

That argument gives the Senate hearing significance beyond the question of Overton’s confirmation. It signals that, if she takes charge, the FDA could be pressed to judge its procedures partly by how quickly they help therapies progress. The emphasis on China also presents the agency as part of the country’s response to international competition in biotechnology, rather than solely as a regulator of medicines.

At the same time, Overton’s prepared remarks describe the FDA’s existing employees as central to the effort. She says she would rely on the agency’s career professionals while seeking changes to the way clinical trials and drug development are handled. The statement therefore combines a call for faster action with an intention to work through the institution’s current workforce.

What senators will hear

The opening statement is an outline of priorities rather than a detailed policy plan. It identifies faster trials, more efficient development and competition with China as connected challenges. It also indicates that Overton views the FDA’s internal processes as an area where improvement could help patients receive treatments sooner.

The Senate hearing will give lawmakers an opportunity to examine that approach as they consider her nomination. The available statement makes clear that she intends to present speed as a measure of the agency’s effectiveness and as a national economic and scientific concern.

STAT reported the contents of the advance statement. Overton’s nomination now places the FDA’s pace of decision-making, the future of Operation Trialblazer and the agency’s response to China’s biotechnology growth among the issues before the committee.